These factors encompass an elevated vector dose exceeding the initial dosage administered during HIV-1 infection, loss of viral accessory proteins that aid in immune evasion during HIV-1 infection, and the stimulation of the cGAS pathway through the presence of DNA within the vector [140]. The gene discussed is CGAS; the disease is HIV-1 infection.